Microbial API Market Size, Share & Trends Analysis Report By Type (Antibiotics, Amino acids, Vitamins, Nucleotides, Organic Acids, Biological Products, Hormones), End-Users, By Region, And Segment Forecasts, 2023 To 2030

Microorganisms conduct fermentation and create secondary metabolites. Adjustments in growth environments can be used to make these organisms covert economical carbon sources (starch, sucrose, glucose, etc.) and nitrogen sources (soybean flour, cotton-seed flour, peptone, etc.) into highly useful key intermediates or microbial APIs (such as antibiotics vitamins, amino acids).

 APIs are the biological/synthetic active constituent of a pharmaceuticals. Popular production techniques include chemical synthesis, fermentation, recombinant DNA, isolation, & natural source recovery. A drug's API is used to treat, detect, mitigate, as well as prevent diseases and is used in various pharmaceuticals for conditions such as oncology, CNS disorders, diabetes, neurological diseases, respiratory and cardiovascular disorders, and others.

The increasing prevalence of chronic illnesses such as Alzheimer's disease and others is expected to drive the demand for microbial API. According to the Alzheimer's  Association, 6.5 million individuals in the U.S. were suffering from Alzheimer’s disease in 2022. It is the sixth leading cause of death in the U.S., and has a higher prevalence rate in people over 65. This figure is expected to increase to 13 million by 2050, increasing the demand for associated drugs and microbial API.

Increased demand for biological products, amino acids, and antibiotics is driving the growth of the global microbial API market. Furthermore, the growing need to fulfill nutritional requirements is anticipated to increase end-user adoption of microbially derived vitamins in the upcoming years. The market demand for microbial APIs is attributed to characteristics such as non-toxicity, ease of availability, and high specificity. Their major application areas include pharmaceutical and biotechnology industries, hospitals, and research facilities. In addition, increased immunization against infectious diseases and expanding applications in the pharmaceutical industry are further driving growth in the microbial API market.

Major companies operating in the microbial API market include Merck & Co., Inc., HGPF, Huaxing, North China Pharmaceutical Co Ltd, Topfond Pharmaceutical Co., Ltd., DSM, Tianjin Tianyao Pharmaceuticals Co., Ltd., CSPC Pharma, KOLON LIFE SCIENCE, Northeast Pharm, Shandong Lukang Pharmaceutical Co., Ltd., Luwei Pharmaceutical Group Co., Ltd., Jiangshan (DSM). Companies are aiming at the expansion of manufacturing plants. However, the stringent FD regulations are hindering the overall market growth and capacity upgradation plants of players in the industry.